View as an RSS Feed
View Derek Lowe's Articles BY TICKER:
ABBV, ABT, ACOR, AFFY, ALNY, AMGN, ARIA, ARNA, ASTX, AVEO, AZN, BIIB, BMS, BTIM, CEPH, CPRX, DNDN, ELN, ESALY, EXEL, GALE, GE, GNBT, GNVC, GS, GSK, ITMN, JNJ, KVPBQ, LLY, MDVN, MEDX, MNKD, MRK, MTXX, MYGN, NTMD, NVO, NVS, OSIR, OSUKF, PFE, PTCT, RBXLF, RBXZF, RDEA, REGN, RHHBY, RNN, RUK, SEPR, SGP, SNSS, SNY, SQNM, SVNTQ, TKPHF, TRGT, VNDA, VPHM, VSTM, WYE
- No Clear Way Forward for Medivation's Alzheimer's Drug
- AstraZeneca Starts to Slash
- Will GSK Take Avandia Off the Market or Not?
- Where Are Merck's Cuts Coming From?
- Sanofi-Aventis Cuts Back
Pharma's Ugly Finances, Part II
on Feb. 9, 2010 • 4 Comments
- How Big Pharma Got in This Fix
- Pfizer's New Alzheimer's Drug: A Black Box Indeed
- GlaxoSmithKline's Malaria Database Deserves More Press
- Carl Icahn's Growing Biogen Front
- GlaxoSmithKline: More Cuts Coming
- Merck's Sirna Acquisition Adds the Kind of Value Wall Street Doesn't See
- First Pharma Bloodletting of 2010: AstraZeneca
- Scorched-Earth Policy at Wyeth's Princeton Site?
- Acorda Should Reap Rewards for MS Drug Ampyra
- Things Can Get Even Worse for Sequenom
- Sirtris Handles Pfizer's Sirtuin Work Less than Admirably
- 3 Different Scenarios for GlaxoSmithKline's Sirtris Investment
- What Did GlaxoSmithKline Get in Return for Buying Sirtris?
- Is Carl Icahn Going for Genzyme?
- The Real Reason for Lilly's R&D Outsourcing
- Read the Novartis / Alcon Fine Print
- Pfizer's Apo-A1 Milano Flop: Typical for Big Pharma Deals
- GE Healthcare's Shameful Libel Suit
- The Historical Success of Growing Big Pharma from Small
- Pfizer's R&D: Spending vs. Productivity
- Do Pfizer's Layoffs Comply with New York Law?
- Competition in Blood - Thinners: Win - Win for Everyone Involved
- Cholesterol Drug Trials: A Victory for Abbott Means a Loss for Merck
- Pfizer's Chemistry Head Count: Lower than Before the Wyeth Merger
- Another Look at Pfizer's Recent Moves
- Pfizer's New Look